Back to Newsroom

Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models

WALTHAM, Mass.- July 30, 2014 – Syndax Pharmaceuticals, Inc. today announced that newly published results demonstrate that in preclinical studies entinostat significantly improved treatment outcomes in mouse tumor models when combined with anti-PD1 and anti-CTLA4 targeted antibodies. The paper from Kim, et al. at The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, titled “Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid derived cells” was published in the journal Proceedings of the National Academy of Sciences (PNAS). The study demonstrated that the combination therapy produced 100 percent inhibition of primary tumors and metastases in aggressive mouse colorectal and breast tumor models. The authors also reported an 80 percent cure rate when epigenetic therapy with entinostat and azacitidine was combined with anti-PD1 and anti-CTLA4 antibodies in an aggressive non-immunogenic metastatic breast cancer mouse model.

Click here to read more